Wedbush Maintains Neutral on NovoCure, Lowers Price Target to $19
Benzinga Newsdesk 6 hours ago
Analyst RatingsNewsPrice Target
Wedbush analyst David Nierengarten maintains NovoCure (NASDAQ:NVCR) with a Neutral and lowers the price target from $20 to $19.
Wedbush analyst David Nierengarten maintains NovoCure (NASDAQ:NVCR) with a Neutral and lowers the price target from $20 to $19.